http://www.gotoper.com/publications/ajho/2014/2014Dec/Gemcitabine-and-Capecitabine-for-Advanced-Adenocarcinoma-of-the-Pancreas
Gemcitabine and Capecitabine for Advanced Adenocarcinoma of the Pancreas

September 19, 2018
Robert D. Levin, MD

Introduction

The current standard of chemotherapy for newly diagnosed patients with advanced pancreatic cancer is either FOLFIRINOX (5-fluorouracil [5-FU], leucovorin, irinotecan, and oxaliplatin) or gemcitabine/nab-paclitaxel regimens, but the 5-year survival rate is less than 5%. Conventional gemcitabine therapy requires weekly visits for patients, while the FOLFIRINOX regimen requires biweekly intravenous infusion therapy, and the gem-citabine/nab-paclitaxel regimen often causes progressive neuropathy, limiting the duration of therapy.

An alternative therapy has been developed that greatly improves the tolerability of chemotherapy, reduces the time burden on patients, and provides better tolerance of the treatment-induced side effects, and yet maintains duration of overall survival (OS). This therapy is fixed-dose-rate infusion of gemcitabine with capecitabine. This therapy was particularly well-tolerated relative to the rather toxic FOLFIRINOX therapy, and relative to the neuropathy common with gemcitabine/nab-paclitaxel regimens, especially in patients with impaired marrow tolerance due to prior radiotherapy, or with pre-existing neuropathy. A therapy of weekly gemcitabine and capecitabine was described by Knox et al1 in the Journal of Clinical Oncology in 2005 for advanced biliary carcinomas, utilizing weekly gemcitabine on days 1 and 8, with capecitabine given at a dosage of 650 mg/m2 twice daily for 14 days; cycles were repeated every 21 days. Prolonged fixed-dose-rate infusions were developed with the knowledge that phosphorylation of gemcitabine into the active gemcitabine tri-phosphate is catalyzed by deoxycytidine kinase, an enzyme that is saturated by 30 minutes. Therefore, enhanced antineoplastic activity requires prolonged infusion times; many physicians during the years 1999 to 2003 studied infusion times ranging from 30 minutes to 24 hours.2-4 Prior studies with 5-FU and with fluo-rodeoxyuridine5 demonstrated that individual dosage tolerances were extremely varied, suggesting that studies with dosage escalations according to individual patient tolerance were needed.

Capecitabine is an oral prodrug of 5-FU that is designed to exploit the differences in activating enzyme (thymidine phosphorylase) activity between tumor and normal tissue that results in a threefold increase in the concentration of the active metabolite in the tumor cell.6 It was generally recognized that the useful chemotherapy drugs available are gemcitabine, 5-FU, oxaliplatin, bevacizumab, nab-paclitaxel, and recently the experimental nanosomal irinotecan MM-398. With few drugs available, the opportunities for development of combination chemotherapy are limited and cures are unlikely. Further development of new drugs for patients is anxiously awaited. Table 1 shows the re-ported OS in the literature.

 

With this background, we developed and piloted an alternative therapy, fixed-dose-rate infusion of gemcitabine with escalating-dose capecitabine, which has the potential to greatly improve tolerability and reduce the time burden on patients. We sought to examine whether this regimen could provide equivalent duration of OS as seen with other contemporary first-line regimens with less toxicity.

METHODS

Patients

Our adult patients with stage IIB to IV pancreatic cancer includ-ed 54 patients with newly diagnosed advanced disease and 25 patients with prior chemotherapy and relapsed disease. These patients received treatment with a combination of gemcitabine and capecitabine. A retrospective case retrieval was used to analyze tumor response, OS, and treatment-related adverse events (AEs). We treated them from February 2008 to November 2013 at the Midwestern Regional Medical Center in Zion, Illinois.

Treatment-related toxicities were graded using the National Cancer Institute Common Toxicity Criteria, version 3 (2003).

Retrospective analysis was conducted after the Midwestern Institutional Review Board confirmed that the data collection was IRB-exempt, with all data collected being de-identified prior to analysis and reporting. As such, this study complied with the International Ethical Guidelines for Biomedical Research In-volving Human Subjects, Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws.

Treatment Schedule

Each chemotherapy cycle consisted of every-4-week gem-citabine 3000 mg/m2 by fixed-rate dose infusion over 3 hours. Capecitabine was dosed at a level tolerated by the patient, usually starting with the dosage of 2000 mg/m2 twice daily for 14 con-secutive days every month. Capecitabine dosage was increased to the highest dose tolerated with less than grade 3 toxicity. Frail patients received decreased dosage in the initial cycle, but escalation in the second cycle to customary doses. To minimize and control toxicities, each patient was instructed in supportive care, antidiarrhea care, and the particular steps needed for minimizing hand-foot syndrome.

Tumor Response

Monthly follow-up visits involved physical examination and standard laboratory tests including complete blood count (CBC), chemistries with liver function tests, and tumor markers. Radiographic studies were performed at 3-month intervals. Pain assessment was conducted using the visual analog scale to determine a decrease in pain levels of a tumor response.15

Statistical Methods

The primary end points of this retrospective study were evidence of tumor response, survival, time to progression, and the preva-lence and grade of treatment-related toxicities. Survival was estimated using the Kaplan-Meier method. Survival was measured from the first cycle of therapy to patient death. The time to progression was measured from the first cycle until radiological evidence of more than 25% increase in the product of cross diameters of a measurable tumor site. Formal RECIST were not sought, as many patients had minimally measurable disease. Date of last follow-up was July 1, 2014. Living patients were censored to July 1, 2014.

RESULTS

Patient Demographics and Treatment History

Seventy-nine patients received therapy for stage IIB-III, recurrent disease, or stage IV pancreatic cancer (Table 2). These patients had a median age of 57.0 years (range, age 36-71 years), and 59% were male. Eighteen patients in this series had stage IIB-III cancer while 61 patients had stage IV disease. The median delay between the diagnosis and the onset of our therapy for the 43 previously untreated patients with stage IV disease was 1.6 +/- 2.5 months (range, 0-12.3 months), while the median delay for the 18 patients with prior chemotherapy was 7.7 +/- 7.5 months (range, of 0-29.8 months). Of the 25 patients with relapsed disease, 4 had progressed after more than 1 chemotherapy regimen and 7 had had prior radiotherapy.

Treatment and Survival

All patients analyzed for survival received at least 2 cycles of capecitabine unless severe toxicity was experienced in the initial cycle. Two patients who had previously received chemotherapy were lost to follow-up after 1 cycle of therapy and are not included in the results. All patients received gemcitabine 3000 mg/m2 over 3 hours on the initial day of each monthly cycle. The highest dosage of capecitabine tolerated was 4 1/2 500-mg tablets twice daily for 14 days,with a standard deviation (SD) of 1.2 tablets twice daily, making a 95% confidence interval (CI) of 2 to 9 tablets twice daily times 14 days. The median number of treatment cycles was 7.2 (range, 2-41 cycles). Thirty-six patients had 6 or more cycles of therapy. As of July 2014, 12 patients were alive. The median survival of all patients was 12.0 months (67% CI, 2.0- 22.1 months; range, 0.8-44.8 months) with a 2-year survival of 9%. In the 53 newly diagnosed patients, the median survival was 11.6 months (67% CI, 2.5-20.7 months; range, 0.8-41.6 months) and a 2-year survival of 5%. The median survival of the patients who relapsed after gemcitabine- capecitabine was 3.6 months (67% CI, 0.3-11.1 months). This is illustrated in the Figure.

The median survival of the 25 patients who had previously received chemotherapy was 13 months (67% CI, 1.0-24.9 months; range, 1.6-44.8 months). There was no statistically significant difference in these survival curves by the log rank test. Twelve patients had prior gemcitabine-containing therapy, often with radiotherapy, and their median survival was 15.2 months. The 14 patients with prior 5-FU-containing therapies had a median survival of 13.0 months, while the 7 patients with prior oxaliplatin- containing regimens had a median survival of 12.8 months. Median survival of patients with stage III disease is delineated in Table 3, and Table 4 lists survival according to subgroups.

Four patients received only 1 cycle of therapy. The first patient had an ECOG performance status of 2 and massive ascites. The second patient had extensive liver metastases with an initial bilirubin of 3. The third patient had massive liver metastases with disease progression during the first cycle. The fourth patient apparently tolerated therapy well, but decided not to return for further chemotherapy for personal reasons.

Safety and Tolerability Treatment-related AEs associated with this regimen included transient leukopenia generally lasting less than a week (Table 5). There was universal alopecia, as well as 3 instances of grade 3 stomatitis, 2 instances of grade 3 hand-foot syndrome, and 1 instance of grade 3 leukopenia lasting longer than 7 days, but on no occasion was scheduled chemotherapy delayed due to toxicity. Capecitabine dosage was decreased in those with grade 3 stomatitis or hand-foot syndrome. Bone marrow support with granulocyte colony-stimulating factor was not routinely utilized.

Sixty-four patients had no nausea or vomiting, 68 had no stomatitis, and 48 had no hand-foot syndrome. Diarrhea was grade 2 in 7 patients and grade 3 in 2 patients. No patients experienced chemotherapyinduced thrombocytopenia. There were no grade 4 treatment-related toxicities. There was no therapyrelated mortality (0 of 79 patients).

Cholangitis and sepsis occurred in patients who had high-degree obstruction of the biliary ducts, occurring universally when leukopenia was absent. All deaths were a result of multiple organ failure due to the disease process. There was no imputation of results for the missing data.

Ten chemotherapy-naïve patients were initially treated with gemcitabine and capecitabine, and following progression received single-agent oxaliplatin at 120 mg/m2 once monthly. Their average duration of freedom from progression to the initial gemcitabine phase was 7.5 months, and 5.5 months to the subsequent oxaliplatin. Median survival for patients in both phases was 13.3 months. This group included 1 patient whose response to the gemcitabine-capecitabine phase was 34.3 months, a pro-longed survival 3 SD above the mean for the group. This patient was considered to be unusually responsive.

This study thus included 5 patients whose survival was longer than 2 SD above the mean of the other patients, suggesting they belonged to a subgroup, the basis of which will be studied in the future.

Conclusion

The chemotherapy regimen of fixed-infusion-rate gemcitabine-and escalting-dose capecitabine offers a well-tolerated regimen for patients utilizing a convenient monthly chemotherapy. This provides a significant increased quality of life for patients who need to receive chemotherapy. It provides comparable survival relative to more toxic contemporary regimens in patients and markedly prolonged survival in a subgroup of patients. This regimen merits a prospective trial, and ultimately should be compared with gemcitabine/nab-paclitaxel or FOLFIRINOX.

We are optimistic that genomic analysis of patients may provide a means to prospectively identify patients with pancreatic cancer whose biological subtype suggests the potential for prolonged survival. These studies are now in progress.

Affiliation: Robert D. Levin, MD, is chief of Medical Oncology at the Midwestern Regional Medical Center, Zion, IL.
Disclosure: Dr. Levin reports no relevant conflicts of interest to disclose.
Address correspondence to: Robert D. Levin, MD, Midwestern Regional Medical Center, 2520 Elisha Avenue, Zion IL. 60099; phone: 847-872-6371; fax: 847-872-6419; email: Robert.Levin@ CTCA-hope.com

References

  1. Knox J, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23:2332-2338.
  2. Akrivakis K, Schmid P, Flath B, et al. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs. 1999;10:525-532.
  3. Schmid P, Akrivakis K, Flath B, et al. Phase II trial of gem-citabine as prolonged infusion in metastatic breast cancer. Anti-cancer Drugs. 1999;10:625-632.
  4. Eckel F, Schmelz R, Erdmann J, et al. Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Cancer Invest. 2003;21: 690-694.      
  5. Levin RD, Gordon JH. Fluorodeoxyuridine with continuous leucovorin infusion. a phase II clinical trial in patients with met-astatic colorectal cancer. Cancer. 1993;72:2895-2901.
  6. Genentech. (2013). Highlights of prescribing information. http://www.gene.com/download/pdf/xeloda_prescribing.pdf. Accessed August 30, 2014.
  7. Gelibter A, Malaguti P, Di Cosimo S, et al. Fixed dose-rate gem-citabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer. 2005;104(6):1237-1245.
  8. Malaguti P, Melella M, Gelibter G, et al. Fixed dose-rate gem-citabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree: series of 106 consecutive patients. J Clin Oncol. 2006;24:18s(June 20 suppl):14099.
  9. Conroy T, Desseigne F, Ychou M, et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic carcinoma. N Engl J Med. 2011;364:1817-1825.
  10. Tudini M, Palluzzi M, Mancini A, et al. Modulation of gem-citabine and oxaliplatin chemotherapy in advanced pancreatic cancer according to CIRS. Presented at: 2010 Gastrointestinal Cancers Symposium. Abstract 253.
  11. Ko A, Dito E, Schillinger B, et al. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas J Clin Oncol. 2006:24(3):379-385.
  12. Von Hoff D, Ervin T, Arena F, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-1703.
  13. Javle M, Yu J, Garrett C, et al. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Brit J Cancer. 2009;100:1842-1845.
  14. Kindler HL, Niedwiecki D, Hollis D, et al., Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622.
  15. Davis M, Walsh D. Cancer pain: how to measure the fifth vital sign. Cleveland Clinic J Med. 2004;71:625-632.